Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: A 3-year experience in real-life practice

BJU International

Volumn 101, Issue 7, 2008, Pages 847-852

  Vallancien, Guy ^a   Emberton, Mark ^b   Alcaraz, Antonio ^c   Matzkin, Haim ^d   Van Moorselaar, R Jeroen A ^e   Hartung, Rudolf ^f   Harving, Niels ^g   Elhilali, Mostafa ^h  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOSPITAL CLÍNIC   (Spain)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

1 blockers; Acute urinary retention; Alfuzosin; BPH; LUTS; Quality of life

Indexed keywords

ALFUZOSIN; ANTIHYPERTENSIVE AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; BLOOD PRESSURE; CLINICAL PRACTICE; DANISH PROSTATE SYMPTOM SCORE FOR SEXUAL FUNCTION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EJACULATION; EJACULATION DISORDER; EUROPE; FATIGUE; GENERAL PRACTITIONER; HEADACHE; HEART RATE; HUMAN; HYPOTENSION; INSTRUMENTATION; MAJOR CLINICAL STUDY; MALAISE; MALE; NOCTURIA; ORTHOSTATIC HYPOTENSION; POSITIONAL DIZZINESS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RISK ASSESSMENT; SCORING SYSTEM; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOM; SYNCOPE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VASODILATATION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DISEASE PROGRESSION; ERECTILE DYSFUNCTION; HUMANS; MALE; NOCTURIA; PATIENT SATISFACTION; PROSTATIC HYPERPLASIA; PROSTATISM; QUALITY OF LIFE; QUINAZOLINES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME; URINARY RETENTION;

EID: 40149091999     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07458.x     Document Type: Article

References (24)

1. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002 59 : 245 50
2. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998 51 : 428 36
3. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003 44 : 637 49
4. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006 97 (Suppl. 2 23 8
5. McConnell JD, Roehrborn CG, Bautista OM et al., Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 98
6. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006 97 : 734 41
7. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int 2006 97 (Suppl. 2 3 6
8. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003 170 : 530 47
9. Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in healthy volunteers. J Urol 2006 176 : 1529 33
10. Andersson KE, Wyllie MG. Ejaculatory dysfunction: why all alpha-blockers are not equal. BJU Int 2003 92 : 876 7
11. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006 97 (Suppl. 2 34 8
12. Roehrborn CG, van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003 92 : 257 61
13. Vallancien G, Emberton M, Harving N et al., Alf-ONE Study Group. Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms. J Urol 2003 169 : 2257 61
14. van Moorselaar RJ, Hartung R, Emberton M et al., Alf-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005 95 : 603 8
15. Emberton M, Elhilali M, Matzkin H et al., Alf-ONE Study Group. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology 2005 66 : 316 22
16. Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G. Response to daily alfuzosin 10 mg predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. J Urol 2006 176 : 1051 6
17. Elhilali M, Emberton M, Matzkin H, Alf-ONE Study Group. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. BJU Int 2006 97 : 513 9
18. Hartung R, Matzkin H, Alcaraz A, Alf-ONE Study Group. Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol 2006 175 : 624 8
19. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007 177 : 1071 7
20. McVary KT, Roehrborn CG, Kaminetzky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007 177 : 1401 7
21. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007 51 : 1717 23
22. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals follow-up study. J Urol 1999 162 : 376 82
23. Emberton M. Definition of at-risk patients: dynamic variables. BJU Int 2006 97 (Suppl. 2 12 5
24. Mottet N, Bressolle F, Delmas V, Robert M, Costa P. Prostatic tissual distribution of alfuzosin patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol 2003 44 : 101 5